Neuraminidase inhibitors

11,590views

Neuraminidase inhibitors

Foundations

Foundations

Introduction to the immune system
Innate immune system
Complement system
Contracting the immune response and peripheral tolerance
Cytokines
Monoclonal antibodies
Antibody classes
Bacterial structure and functions
B-cell development
B-cell activation, differentiation, and contraction
T-cell development
T-cell activation
B- and T-cell memory
MHC class I and MHC class II molecules
Thymus histology
Cell cycle
Mitosis and meiosis
DNA replication
DNA damage and repair
DNA mutations
Cell membrane
Free radicals and cellular injury
Hypoxia
Necrosis and apoptosis
Inflammation
Crohn disease
Gout
Gout and pseudogout: Pathology review
Inclusion body myopathy
Inflammatory bowel disease: Pathology review
Papulosquamous and inflammatory skin disorders: Pathology review
Myasthenia gravis
Systemic lupus erythematosus
Type I hypersensitivity
Type II hypersensitivity
Type III hypersensitivity
Type IV hypersensitivity
Serum sickness
Anaphylaxis
Graft-versus-host disease
Systemic lupus erythematosus (SLE): Pathology review
Pemphigus vulgaris
Stevens-Johnson syndrome
Rheumatic heart disease
Heart failure: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Body fluid compartments
Movement of water between body compartments
Hyponatremia
Pulmonary edema
Lymphedema
Coagulation (secondary hemostasis)
Platelet plug formation (primary hemostasis)
Erythropoietin
Hemophilia
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Blood components
Protein C deficiency
Protein S deficiency
Metaplasia and dysplasia
Multiple endocrine neoplasia: Pathology review
Oncogenes and tumor suppressor genes
Amyloidosis
Atrophy, aplasia, and hypoplasia
Environmental and chemical toxicities: Pathology review
Medication overdoses and toxicities: Pathology review
Multiple endocrine neoplasia
Substance misuse and addiction: Clinical
Toxidromes: Clinical
Deep vein thrombosis and pulmonary embolism: Pathology review
Heparin-induced thrombocytopenia
Myocardial infarction
Shock
Arterial disease
Atherosclerosis and arteriosclerosis: Pathology review
Carbohydrates and sugars
Childhood nutrition and obesity: Information for patients and families (The Primary School)
Fat-soluble vitamin deficiency and toxicity: Pathology review
Folate (Vitamin B9) deficiency
Iron deficiency anemia
Osteomalacia and rickets
Vitamin B12 deficiency
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Wernicke-Korsakoff syndrome
Zinc deficiency and protein-energy malnutrition: Pathology review
Burns: Clinical
Burns
Hyperplasia and hypertrophy
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Klinefelter syndrome
Turner syndrome
Angelman syndrome
Prader-Willi syndrome
Fragile X syndrome
DiGeorge syndrome
Phenylketonuria (NORD)
Homocystinuria
Maple syrup urine disease
Disorders of fatty acid metabolism: Pathology review
Ornithine transcarbamylase deficiency
Post-transplant lymphoproliferative disorders (NORD)
Cytomegalovirus infection after transplant (NORD)
Epigenetics
Gene regulation
Independent assortment of genes and linkage
Inheritance patterns
Mendelian genetics and punnett squares
Evolution and natural selection
Antiphospholipid syndrome
Celiac disease
Graves disease
Multiple sclerosis
Diabetes mellitus
Chronic granulomatous disease
Immunodeficiencies: Clinical
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Candida
Mycobacterium tuberculosis (Tuberculosis)
Tuberculosis: Pathology review
Pneumonia: Pathology review
Pneumonia
Salmonella (non-typhoidal)
Viral structure and functions
Hepatitis medications
Herpesvirus medications
Neuraminidase inhibitors
HIV (AIDS)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Integrase and entry inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Protease inhibitors
Vaccinations: Clinical
The flu vaccine: Information for patients and families
Vaccinations

Transcript

Watch video only

Neuraminidase inhibitors are antiviral medications mainly used to treat influenza, which is the virus that causes the flu.

There are three types of influenza viruses that infect humans; type A, type B, and type C, and each one has a slightly different genome and set of proteins.

Now, neuraminidase inhibitors work by preventing the release of new viruses from infected cells, thereby limiting the duration of the illness.

Alright, first let’s focus on influenza A and influenza B.

These viruses have two types of glycoproteins on their protective envelope: H protein, or hemagglutinin; and N protein, or neuraminidase.

When the flu virus enters the body, it uses hemagglutinin to bind to sialic acid sugars on the surface of epithelial cells in the upper respiratory tract.

Once bound, the cell swallows up the virus in a process called endocytosis.

Next, the virus releases its viral RNA which moves into the cell’s nucleus.

Now, these RNAs are negative-sense, meaning they need to be transcribed by RNA polymerase into positive-sense mRNA strands.

These strands leave the nucleus and are translated into proteins by ribosomes.

These proteins are then assembled into new viruses.

Now that we have a cell that’s pretty much a virus-producing factory, it will continue to produce more and more viruses which bud off the host cell’s plasma membrane and leave the body.

However, the same hemagglutinin that allowed the virus to attach to the sialic acid sugar on the cell surface, can bind to these sugars again and prevent the viruses from leaving the host cell.

So, in order to be released, the virus uses the neuraminidase proteins to cleave the sialic acid and free itself.

So in short, hemagglutinin allows the virus to enter the cell, while neuraminidase lets the virus leave the cell.

Now, neuraminidase inhibitors, as their name implies, bind and inhibit the enzyme neuraminidase, thereby preventing the release of new viruses.

Common medications in this class include oseltamivir, which is taken perorally as a pill, and zanamivir, which is taken as a powder inhaled by mouth.

Key Takeaways

Neuraminidase inhibitors are antiviral medications used for the treatment and prophylaxis of influenza A and influenza B, which are known to cause the flu. Neuraminidase inhibitors work by blocking an enzyme called neuraminidase produced by the influenza virus. The function of neuraminidase is to help new viruses to get released from infected cells, and so, its inhibition will disrupt further infection of the host's cells. Examples of neuraminidase inhibitors include oseltamivir, and zanamivir.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients" European Respiratory Journal (2015)
  5. "Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013" Antiviral Therapy (2015)
  6. "Clinical use of approved influenza antivirals: therapy and prophylaxis" Influenza and Other Respiratory Viruses (2012)